title: Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
authors: S
authors: S
authors: Ettou
authors: E
authors: E
authors: Audureau
authors: C
authors: C
authors: Humbrecht
authors: B
authors: B
authors: Benet
authors: H
authors: H
authors: Jammes
authors: T
authors: T
authors: Clozel
authors: V
authors: V
authors: Bardet
authors: C
authors: C
authors: Lacombe
authors: F
authors: F
authors: Dreyfus
authors: P
authors: P
authors: Mayeux
authors: E
authors: E
authors: Solary
authors: M
authors: M
authors: Fontenay
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D015415:Biomarkers; D018899:CpG Islands; D019175:DNA Methylation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D011401:Promoter Regions, Genetic; D016016:Proportional Hazards Models; D012306:Risk; D019014:fas Receptor / Q000032:analysis / Q000235:genetics*
chemical_list: D000964:Antimetabolites, Antineoplastic; D015415:Biomarkers; D019014:fas Receptor; D001374:Azacitidine